Shots:

• The approval is based on five studies assessing Lokelma vs PBO in patients with hyperkalaemia
• The study resulted in onset of action was at 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours- 92% of patients achieved normal potassium level in 48 hrs. and was effective for 12 mos.
• Lokelma insoluble- non-absorbed sodium zirconium silicate formerly known as ZS-9- and has received EU’s approval on 22 Mar-2018

Ref: AstraZeneca | Image: AstraZeneca